Complications with Diabetes and Diabetes Insipidus

Complications of Diabetes and Diabetes Insipidus

Overview of Diabetes

  • Types of Diabetes: Two main forms: Type 1 and Type 2.

    • Type 1 Diabetes:

    • Autoimmune condition.

    • Immune system attacks insulin-producing beta cells in the pancreas.

    • Leads to deficiency of insulin, the hormone responsible for regulating blood sugar levels.

    • Typically presents in childhood or adolescence.

    • Requires lifelong insulin therapy.

    • Type 2 Diabetes:

    • Characterized by insulin resistance, where body cells resist insulin effects.

    • Often presents with a relative deficiency in insulin production.

    • Commonly associated with obesity, sedentary lifestyle, and genetic factors.

    • Usually develops later in life.

    • Managed via lifestyle changes, oral medications, and sometimes insulin over time.

  • Prevalence: Type 2 diabetes accounts for 90-95% of diabetes cases.

Diagnostic Criteria for Diabetes Mellitus

  • Four main criteria:

    • Fasting blood glucose level > 126 mg/dL (no caloric intake for at least 8 hours).

    • Random blood glucose level > 200 mg/dL with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia).

    • Plasma glucose level > 200 mg/dL two hours after an oral glucose tolerance test.

    • Hemoglobin A1C level > 6.5%, reflecting average blood glucose levels over the past 2-3 months.

Management of Diabetes

  • Involves multiple approaches:

    • Diet and nutrition therapy.

    • Regular exercise.

    • Blood glucose monitoring.

    • Administration of medications, including insulin and oral agents.

    • Patient education and routine screening for complications.

    • Addressing psychosocial issues.

  • Primary goals:

    • Maintain blood glucose levels within target range.

    • Prevent complications (both acute and long-term).

    • Control risk factors for cardiovascular disease (blood pressure, cholesterol).

    • Enhance patient quality of life through self-management and education.

Insulin Therapy

  • Types of Insulin:

    • Rapid-acting insulins (e.g., Lispro, Aspart):

    • Onset: 10-30 minutes.

    • Peak: 30 minutes - 3 hours.

    • Duration: 3-5 hours.

    • Short-acting insulins (e.g., Regular insulin):

    • Onset: 30 minutes - 1 hour.

    • Peak: 2 - 5 hours.

    • Duration: 5-8 hours.

    • Intermediate acting insulins (e.g., NPH):

    • Onset: 1.5 - 4 hours.

    • Peak: 4 - 12 hours.

    • Duration: 12-18 hours.

    • Long acting insulins (e.g., Glargine, Detemir):

    • Less peak effect.

    • Duration: 18-24+ hours.

    • Premixed insulins: 70/30, 50/50 combinations of rapid/short-acting with intermediate insulins.

    • Concentrated formulations: U-500 and U-300 available for resistant hypoglycemia cases.

    • Inhaled insulin: Briefly used; currently discontinued.

  • Insulin Pumps:

    • Portable device providing continuous subcutaneous insulin.

    • Mimics physiological insulin secretion with programmed basal rates and bolus doses during meals.

    • Requires regular changes of infusion set every 2-3 days.

    • Offers better glycemic control with fewer injections than multiple daily injections.

  • Pancreas Transplantation:

    • Surgical procedure involving transplantation of a healthy pancreas from a deceased donor.

    • Performed in patients with Type 1 diabetes and end-stage renal disease undergoing or having undergone kidney transplant.

    • Restores natural insulin production, eliminates need for injections, improves quality of life, and prevents complications.

    • Requires lifelong immunosuppressant therapy to prevent organ rejection, introducing its own risks and side effects.

  • Islet Cell Transplantation: Involves transplanting insulin-producing islet cells into the liver.

Diabetic Ketoacidosis (DKA)

  • Definition: A critical complication due to insulin deficiency primarily seen in Type 1 diabetics.

    • Pathophysiology:

    • Lack of insulin prevents glucose utilization by cells leading to high blood sugar levels.

    • Insulin deficiency enhances lipolysis, increasing free fatty acids.

    • Free fatty acids lead to ketogenesis, producing ketone bodies (e.g., acetate, beta-hydroxybutyrate, acetone).

    • Ketone body accumulation induces metabolic acidosis.

    • Presentation:

    • Blood glucose levels typically > 250 mg/dL, often exceeding 600 mg/dL.

    • Symptoms include polyuria, polydipsia, dehydration, nausea, vomiting, abdominal pain, Kussmaul respirations, fruity breath odor, fatigue, tachycardia, hypotension.

    • Laboratory Findings:

    • Hyperglycemia, presence of ketones, metabolic acidosis, and dehydration.

  • Management of DKA:

    • Inpatient hospitalization generally required for severe cases.

    • Initial Emergency Management:

    • Ensure patent airway and adequate oxygenation.

    • Aggressive fluid resuscitation using isotonic fluids (0.9% normal saline) at 1-1.5 liters over the first hour.

    • Continuous IV insulin infusion to gradually lower blood glucose levels (typically 0.1 units/kg/hour).

    • Correct electrolyte imbalances, especially potassium, and monitor for complications (e.g., cerebral edema).

Hyperosmolar Hyperglycemic Syndrome (HHS)

  • Definition: A serious condition characterized by extreme hyperglycemia (>600 mg/dL) without significant metabolic acidosis.

    • Pathophysiology:

    • Relative insulin deficiency leads to hyperglycemia and hyperosmolarity in the extracellular fluid, causing dehydration of cells.

    • Common causes:

    • Infections (e.g., UTIs, pneumonia), newly diagnosed type 2 diabetes, inadequate fluid intake in elderly or cognitively impaired patients.

  • Management of HHS:

    • Rapid rehydration with fluids (0.9% saline or hypotonic saline). Large volumes often required.

    • Administer insulin at lower doses than in DKA to gradually lower blood glucose levels.

    • Monitor and correct electrolyte imbalances, particularly potassium.

    • Important to watch for fluid overload, especially in older patients with comorbid cardiac or renal issues.

Diabetes Insipidus (DI)

  • Definition: Condition caused by an imbalance in body water regulation due to insufficient antidiuretic hormone (ADH) (vasopressin).

    • Types of DI:

    • Central DI: Caused by inadequate production or release of ADH.

    • Nephrogenic DI: Kidneys fail to respond properly to circulating ADH due to various causes (e.g., genetic defects, medications).

  • Presentation: Both types result in excessive urination (polyuria), leading to hyperosmolar blood and increased thirst (polydipsia).

  • Management of DI:

    • Central DI: Administer desmopressin (synthetic ADH), given orally, IV, or as a nasal spray, adjusting dose to minimize polyuria without causing water intoxication.

    • Nephrogenic DI: Manage fluid balance through controlled intake, use of thiazide diuretics, NSAIDs, and dietary sodium restriction.

    • Both types require regular monitoring of serum and urine osmolality and sodium levels.

  • Conclusion: Monitoring and treatment are critical for preventing severe dehydration and associated complications. Inadequate treatment can lead to life-threatening situations, necessitating prompt and accurate management steps.

Final Notes

  • Encourage patients to reach out with questions regarding their management of diabetes or any complications.